Barinthus Biotherapeutics plc
NGM: BRNSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Barinthus Biotherapeutics plc's price action across multiple timeframes using regression channels and statistical scoring.
Get BRNS Z-Score →About Barinthus Biotherapeutics plc
Healthcare
Biotechnology
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
📊 Fundamental Analysis
Barinthus Biotherapeutics plc demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -65.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.57, BRNS currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $0.51 - $2.92).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$23.18M
Trailing P/E
--
Forward P/E
-0.49
Beta (5Y)
-0.60
52W High
$2.92
52W Low
$0.51
Avg Volume
44K
Day High
Day Low